Table 2.

CV risk algorithms of the patients with axSpA.

	Entire axSpA population (n = 295)	axSpA without CV event (n = 272)	axSpA with CV event (n = 23)	P
CUORE	2.2 (0.9–6)	2 (0.9–5.4)	4.95 (1.7–12.7)	0.01
CUORE*1.5	3.3 (1.35–9)	3 (1.35–8.1)	7.425 (2.55–19.05)	0.01
FRS	6.8 (3.8–15.6)	6.5 (3.5–15)	13.35 (6.7–23.8)	0.02
FRS*1.5	10.2 (5.7–23.4)	9.75 (5.25–22.5)	20.025 (10.05–35.7)	0.02
QRISK2	4.1 (1.7–12.3)	3.65 (1.5–10.7)	12.5 (5.8–22.3)	0.002
QRISK2-RA	5.25 (2.25–15.65)	4.75 (2–13.7)	16.16 (7.6–28)	0.002
QRISK3	3.7 (1.5–10.9)	3.3 (1.4–10.1)	12.25 (5–20)	0.002
QRISK3-RA	4.6 (1.9–13.25)	4.1 (1.7–12.3)	14.95 (6.1–24)	0.002
RRS	3 (2–7)	2.5 (2–7)	6.5 (4–12)	0.006
RRS*1.5	4.5 (3–10.5)	3.75 (3–10.5)	9.75 (6–18)	0.006
ASSIGN	6 (4–13)	6 (3–13)	13 (6–28)	0.006
ASSIGN-RA	8 (4–16)	7 (4–16)	16.5 (7–35)	0.004
HeartScore	1 (1–2)	1 (1–2)	1 (1–4)	0.047
HeartScore*1.5	1.5 (1.5–3)	1.5 (1.5–3)	1.5 (1.5–6)	0.047

axSpA axial spondyloarthritis; FRS Framigham risk score; RA rheumatoid arthritis; RRS Reynolds risk score; Score Systematic Coronary Risk Evaluation.